Payment overview · 2025
General Payments
$151.85
8 reported records · 6 companies
Healthcare provider profile · identity verified
Wafa Afif Abbud, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FLINT, MI · NPI 1871581322
Verified facts
What the public records show
CMS Open Payments records show Wafa Afif Abbud, MD received $151.85 in general payments during 2025 across 8 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 29.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 338 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $44.94 | 29.6% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $42.52 | 28.0% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.78 | 11.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.74 | 11.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.97 | 10.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.90 | 9.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $151.85 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $44.94 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $42.52 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $42.52 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.74 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.97 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.97 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 338 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
144 | 41 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
338 | 71 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
136 | 43 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 895 | 220 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 683 | 222 |
| Atorvastatin Calcium | Atorvastatin Calcium | 608 | 189 |
| Amlodipine Besylate | Amlodipine Besylate | 578 | 185 |
| Omeprazole | Omeprazole | 471 | 163 |
| Metformin Hcl | Metformin Hcl | 451 | 154 |
| Lisinopril | Lisinopril | 409 | 129 |
| Simvastatin | Simvastatin | 377 | 114 |
| Jardiance | Empagliflozin | 338 | 97 |
| Ozempic | Semaglutide | 338 | 71 |
| Losartan Potassium | Losartan Potassium | 298 | 99 |
| Metoprolol Tartrate | Metoprolol Tartrate | 295 | 99 |
| Gabapentin | Gabapentin | 289 | 99 |
| Potassium Chloride | Potassium Chloride | 270 | 93 |
| Metoprolol Succinate | Metoprolol Succinate | 243 | 74 |
| Hydrochlorothiazide | Hydrochlorothiazide | 242 | 77 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 239 | 67 |
| Trulicity | Dulaglutide | 207 | 45 |
| Irbesartan | Irbesartan | 195 | 62 |
| Trazodone Hcl | Trazodone Hcl | 185 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 181 | 62 |
| Montelukast Sodium | Montelukast Sodium | 178 | 61 |
| Furosemide | Furosemide | 161 | 74 |
| Fluticasone Propionate | Fluticasone Propionate | 152 | 84 |
| Farxiga | Dapagliflozin Propanediol | 144 | 41 |
| Sertraline Hcl | Sertraline Hcl | 138 | 48 |
| Eliquis | Apixaban | 136 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 134 | 53 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 132 | 39 |
| Tramadol Hcl | Tramadol Hcl | 130 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 129 | 40 |
| Pravastatin Sodium | Pravastatin Sodium | 128 | 38 |
| Famotidine | Famotidine | 120 | 49 |
| Alprazolam | Alprazolam | 112 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 103 | 44 |
| Spironolactone | Spironolactone | 103 | 32 |
| Carvedilol | Carvedilol | 102 | 38 |
| Mounjaro | Tirzepatide | 97 | 25 |
| Atenolol | Atenolol | 91 | 26 |
| Allopurinol | Allopurinol | 86 | 27 |
| Nifedipine Er | Nifedipine | 86 | 34 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 85 | 27 |
| Fluconazole | Fluconazole | 84 | 52 |
| Methylprednisolone | Methylprednisolone | 81 | 74 |
| Ezetimibe | Ezetimibe | 78 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 71 | 20 |
| Meloxicam | Meloxicam | 70 | 41 |
| Tizanidine Hcl | Tizanidine Hcl | 68 | 44 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 66 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 63 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 59 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 56 | 18 |
| Bupropion Hcl Sr | Bupropion Hcl | 55 | 21 |
| Prednisone | Prednisone | 52 | 39 |
| Azithromycin | Azithromycin | 51 | 46 |
| Enalapril Maleate | Enalapril Maleate | 51 | 14 |
| Raloxifene Hcl | Raloxifene Hcl | 51 | 11 |
| Xarelto | Rivaroxaban | 50 | 14 |
| Chlorthalidone | Chlorthalidone | 48 | 15 |
| Donepezil Hcl | Donepezil Hcl | 48 | 18 |
| Alendronate Sodium | Alendronate Sodium | 47 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 44 | 14 |
| Glimepiride | Glimepiride | 43 | 20 |
| Clonazepam | Clonazepam | 42 | 12 |
| Finasteride | Finasteride | 42 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | 14 |
| Nystatin | Nystatin | 42 | 25 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 42 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 41 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 40 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 40 | 20 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 39 | 13 |
| Meclizine Hcl | Meclizine Hcl | 38 | 24 |
| Warfarin Sodium | Warfarin Sodium | 38 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 37 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 35 | 13 |
| Valsartan | Valsartan | 33 | 11 |
| Bupropion Xl | Bupropion Hcl | 32 | 11 |
| Ramipril | Ramipril | 31 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 30 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 30 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 30 | suppressed |
| Lovastatin | Lovastatin | 30 | suppressed |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 29 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | 14 |
| Droplet Pen Needle | Pen Needle, Diabetic | 29 | 15 |
| Metformin Hcl Er | Metformin Hcl | 28 | 12 |
| Nadolol | Nadolol | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Methotrexate | Methotrexate Sodium | 27 | suppressed |
| Sucralfate | Sucralfate | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | 16 |
| Temazepam | Temazepam | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 23 | 13 |
| Acyclovir | Acyclovir | 22 | suppressed |
| Brilinta | Ticagrelor | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Lorazepam | Lorazepam | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 17 |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Invokana | Canagliflozin | 20 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | 17 |
| Morphine Sulfate Er | Morphine Sulfate | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Calcitriol | Calcitriol | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Gemtesa | Vibegron | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | 12 |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Clotrimazole | Clotrimazole | 15 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 13 |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 14 |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | 12 |
| Glipizide Er | Glipizide | 14 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 12 |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Mesalamine Er | Mesalamine | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ambien Cr | Zolpidem Tartrate | 11 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $151.85 · 8 records | Bayer Healthcare Pharmaceuticals Inc. | AIRSUPRA, Cologuard Collection Kit, Kerendia, NURTEC ODT, Ozempic, REXULTI, Rybelsus, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error